Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery.
Publication/Presentation Date
9-13-2019
Abstract
It remains disputable about perioperative use of renin-angiotensin system inhibitors (RASi) and their outcome effects. This multicenter retrospective cohort study examines association between use of perioperative RASi and outcomes in patients undergoing coronary artery bypass graft and/or valve surgery. After the exclusion, the patients are divided into 2 groups with or without preoperative RASi (PreRASi, n = 8581), or 2 groups with or without postoperative RASi (PostRASi, n = 8130). With using of propensity scores matching to reduce treatment selection bias, the study shows that PreRASi is associated with a significant reduction in postoperative 30-day mortality compared with without one (3.41% vs. 5.02%); PostRASi is associated with reduced long-term mortality rate compared with without one (6.62% vs. 7.70% at 2-year; 17.09% vs. 19.95% at 6-year). The results suggest that perioperative use of RASi has a significant benefit for the postoperative and long-term survival among patients undergoing cardiac surgery.
Volume
10
Issue
1
First Page
4202
Last Page
4202
ISSN
2041-1723
Published In/Presented At
Ding, Q., Zhang, Z., Liu, H., Nie, H., Berguson, M., Goldhammer, J. E., Young, N., Boyd, D., Morris, R., & Sun, J. (2019). Perioperative use of renin-angiotensin system inhibitors and outcomes in patients undergoing cardiac surgery. Nature communications, 10(1), 4202. https://doi.org/10.1038/s41467-019-11678-9
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
31519895
Department(s)
Administration and Leadership
Document Type
Article